Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Businesses, Employers Sometimes Split On Health Reform
Employers around the country are split on supporting or opposing health reform "reducing the force of an opposition push," just as business lobbying heats up in the fight, The Washington Post reports.
generic viagra online
Swine Flu: Health Departments Get Mixed Marks For Using Web To Communicate About Crisis, Study Finds
State and local health departments get mixed marks for efforts to convey information about the H1N1 virus to the public using their Web sites immediately after U.S. officials declared a public health emergency in April, according to a new RAND Corporation study.
News of the day
Medicare Payment Rates Cause Concern
Legislation seeks to fix Medicare payment rates for doctors, who are routinely underpaid for services in California, while hearings in South Dakota focus on Medicare reimbursement issues in rural areas.
Sexual Health

Kinex Pharmaceuticals To Present At ASCO 2009 Annual Meeting

Kinex Pharmaceuticals will present results from a Phase 1 clinical study with KX2-391, at the ASCO 2009 Annual Meeting in Orlando, on May 29, 2009. The study was carried out at MD Anderson, Roswell Park Cancer Institute (RPCI) and Fox Chase Cancer Center. Dr. Alex Adjei, the Principal Investigator from RPCI will deliver the presentation entitled "Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies." The presentation will provide data from this multi-center Phase 1 trial that utilized the standard 3+3 design to determine the Maximum Tolerated Dose (MTD), safety, and pharmacokinetics (PK) of KX2-391 in patients with refractory solid tumors. Patients who responded to treatment will be highlighted. This presentation was designated as Best of ASCO(R) which features high-impact abstracts from the 2009 ASCO Annual Meeting that represent the most relevant, cutting-edge science in oncology today. This information has been selected to be presented at meetings in the US and internationally because it highlights the latest scientific findings in primary disease sites and practice-changing advances in cancer prevention and treatment. Kinex Pharmaceuticals is a drug discovery and development company that is focused on next generation drugs to treat cancer and immuno-inflammatory diseases. The Company has utilized its platform technologies to identify highly selective inhibitors of therapeutically relevant targets that are involved in signal transduction and cell cycle control. Kinex Pharmaceuticals


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009